Last edition
News about "astroenteropancreatic neuroendocrine tumours"
Bristol Myers Squibb Reports Positive RYZ101 Phase 3 Results
Bristol Myers Squibb reports positive interim results from the Phase 3 ACTION-1 trial of investigational radiopharmaceutical therapy RYZ101 in patients with GEP-NETs.
Astroenteropancreatic Neuroendocrine Tumours | 14/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members